Revenue: As of FY2025 Q3, the actual value is USD 54.48 B, beating the estimate of USD 51 M.EPS: As of FY2025 Q3, the actual value is USD 0.17, beating the estimate of USD 0.045.EBIT: As of FY2025 Q3, the actual value is USD 10.02 B.<h3>Segment Revenue</h3><ul><li>Product Revenue, Net: $51.9 million for the three months ended September 30, 2025, compared to $56.1 million for the same period in 2024, primarily due to a decrease in product supply revenue to international licensees, partially offset by an increase in domestic sales.</li><li>Royalty Revenue: $2.6 million for the three months ended September 30, 2025, compared to $24.4 million for the same period in 2024, primarily due to timing of sales made into China by sub-licensees.</li></ul><h3>Operational Metrics</h3><ul><li>Net Income: $8.8 million for the three months ended September 30, 2025, compared to $20.3 million for the same period in 2024.</li><li>Operating Costs and Expenses: $44.9 million for the three months ended September 30, 2025, compared to $58.5 million for the same period in 2024.</li><li>Research and Development Expenses: $15.9 million for the three months ended September 30, 2025, compared to $12.6 million for the same period in 2024, primarily due to increased alisertib study activity.</li></ul><h3>Cash Flow</h3><ul><li>Operating Cash Flow: $27.4 million for the nine months ended September 30, 2025, compared to $23.3 million for the same period in 2024.</li><li>Investing Activities: Net cash used was $9.2 million for the nine months ended September 30, 2025, primarily due to the purchase of available-for-sale securities.</li><li>Financing Activities: Net cash used was $33.9 million for the nine months ended September 30, 2025, primarily due to the payment of principal and exit fees on debt with Athyrium.</li></ul><h3>Future Outlook and Strategy</h3><ul><li>Core Business Focus: The company plans to continue the development of alisertib, initially targeting small cell lung cancer and hormone receptor-positive breast cancer. The company also aims to sustain operations and commercialize neratinib successfully.</li><li>Non-Core Business: The company is exploring additional marketing efforts and potential acquisitions of additional drug candidates, which may require additional funding.</li><li>Priority: The company intends to satisfy near-term liquidity requirements through existing cash, cash equivalents, and marketable securities, along with proceeds from product sales, royalties, and sub-license milestone payments.</li></ul>

Puma BioTech | 10-Q: FY2025 Q3 Revenue Beats Estimate at USD 54.48 B